All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On behalf of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), the Lymphoma Hub was pleased to speak with Stephen Ansell, Mayo Clinic, Rochester, US, who chaired a discussion on, How and when to treat patients with refractory or progressive Waldenstrom's macroglobulinemia (WM)? This discussion also featured Christian Buske, Monique Minnema, Sheeba Koshy Thomas, and Jorge J. Castillo.
How and when to treat patients with refractory or progressive WM
Minnema begins by discussing why treatment should only be restarted after measuring each individual patient’s IgM level, a vital indicator of disease progression. Both Minnema and Thomas place importance on the return of symptoms being a useful gauge to assess whether treatment should be restarted. Castillo remarks that readministering a prior regimen is a viable approach only if patients achieve durable responses and treatment is tolerated; however, in cases of relapsed disease, treatment with a different mechanism of action is often the next step. For example, treatment with chemoimmunotherapy and Bruton’s tyrosine kinase (BTK) inhibitors could be used as first and second-line treatments, respectively. Castillo also highlights BTK inhibitors as good follow-up therapy options. Finally, Buske covers novel treatment options following progression on ibrutinib, including the use of a non-covalent BTK inhibitors such as pirtobrutinib, immunochemotherapy, or venetoclax.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox